Synonyms: compound 1 [WO2023196910]
Compound class:
Synthetic organic
Comment: The chemical structure for neladalkib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as an anaplastic lymphoma kinase (ALK) inhibitor with potential antineoplastic action. It is claimed in Nuvalent's patent WO2023196910 [1]. Nuvalent's pipeline declares one ALK inhibitor, NVL-655, so we suspect that this may be neladalkib.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
NVL-655 is a clinical lead for the treatment of solid tumours with activating ALK mutations or gene rearrangements. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05384626 | A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/Phase 2 Interventional | Nuvalent Inc. |